Pulmonx Q3 2024 revenue $20.4M (+15% YoY), net loss $14.1M

Pulmonx Corp

2024-Q3 EPS reported -$1.11 revenue$60,024,000

Worldwide revenue $20.4M, up 15% YoY; U.S. revenue $13.8M (+17% YoY); international $6.6M (+12%).
Gross margin 74% unchanged YoY; net loss $14.1M ($0.36 loss per share) vs $14.9M ($0.39) in Q3 2023.
Adjusted EBITDA loss $8.1M vs $9.0M in Q3 2023; cash & marketable securities $107.8M as of Sep 30.
Full-year 2024 revenue guidance reaffirmed $81M-$84M; op ex guidance narrowed to $122M-$124M.
Added 15 new Zephyr Valve U.S. treatment centers; AeriSeal CONVERT trial showed 77.6% conversion rate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.